TD Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-6,600
| Closed | -$673K | – | 1469 |
|
|
2023
Q2 | $673K | Sell |
6,600
-2,268
| -26% | -$215K | ﹤0.01% | 1208 |
|
|
2023
Q1 | $806K | Sell |
8,868
-4,052
| -31% | -$238K | ﹤0.01% | 1173 |
|
|
2022
Q4 | $491K | Buy |
12,920
+984
| +8% | +$33.9K | ﹤0.01% | 1288 |
|
|
2022
Q3 | $299K | Hold |
11,936
| – | – | ﹤0.01% | 1368 |
|
|
2022
Q2 | $363K | Sell |
11,936
-1,514
| -11% | -$45.2K | ﹤0.01% | 1338 |
|
|
2022
Q1 | $441K | Sell |
13,450
-21,910
| -62% | -$650K | ﹤0.01% | 1353 |
|
|
2021
Q4 | $932K | Buy |
35,360
+8,842
| +33% | +$684K | ﹤0.01% | 1291 |
|
|
2021
Q3 | $2.67M | Sell |
26,518
-247
| -0.9% | -$29K | ﹤0.01% | 1001 |
|
|
2021
Q2 | $3.35M | Sell |
26,765
-2,823
| -10% | -$319K | ﹤0.01% | 937 |
|
|
2021
Q1 | $2.95M | Buy |
29,588
+2,740
| +10% | +$320K | ﹤0.01% | 985 |
|
|
2020
Q4 | $3.32M | Buy |
26,848
+5,851
| +28% | +$769K | ﹤0.01% | 893 |
|
|
2020
Q3 | $2.05M | Buy |
20,997
+1,000
| +5% | +$125K | ﹤0.01% | 901 |
|
|
2020
Q2 | $3.12M | Sell |
19,997
-1,100
| -5% | -$167K | ﹤0.01% | 767 |
|
|
2020
Q1 | $3.04M | Sell |
21,097
-12,000
| -36% | -$2.32M | 0.01% | 733 |
|
|
2019
Q4 | $6.77M | Buy |
33,097
+5,644
| +21% | +$1.03M | 0.01% | 650 |
|
|
2019
Q3 | $2.2M | Buy |
27,453
+7,716
| +39% | +$655K | ﹤0.01% | 889 |
|
|
2019
Q2 | $1.86M | Buy |
19,737
+3,924
| +25% | +$339K | ﹤0.01% | 920 |
|
|
2019
Q1 | $1.35M | Buy |
15,813
+200
| +1% | +$16.6K | ﹤0.01% | 985 |
|
|
2018
Q4 | $876K | Buy |
15,613
+300
| +2% | +$18.3K | ﹤0.01% | 1089 |
|
|
2018
Q3 | $1.25M | Buy |
+15,313
| New | +$1.08M | ﹤0.01% | 1110 |
|
Other funds holding RETA
TD Asset Management's RETA Position: Q3 2023 in Review
TD Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 6,600 shares — an estimated $673K sold.
TD Asset Management first reported a position in RETA in Q3 2018 and held it in 20 quarters. The position peaked at $6.77M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- TD Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- TD Asset Management sold 6,600 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $673K.
- TD Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 20 quarters.
- TD Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $6.77M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on TD Asset Management's 13F filing for Q3 2023, filed 27 Oct 2023.